CHELMSFORD, Mass., Nov. 15, 2010 /PRNewswire/ — Magellan
Biosciences, a global manufacturer of products designed to make
diagnostic testing easier, more cost-effective, and less labor
intensive, announced that it will preview an innovative, new
immunoassay processing system in the North American Pavilion
(Hall 3 D45, Stands 3-6) at MEDICA 2010, which opens
tomorrow in Dusseldorf, Germany. Magellan designed the fully
automated system, Project 24 (its development name),
to quickly and easily process 96-well microplates for total assay
optimization. Project 24 is currently in the final stages of
development and not yet available for customer orders.
“We are very excited to share our next-generation platform with
the marketplace,” said Magellan Biosciences President and CEO,
Hiroshi Uchida, Ph.D. “Project 24 optimizes
microplate ELISA testing by bringing true automation and
extraordinary ease-of-use to what historically has been a tedious
and time-consuming process. We have removed all of the manual
set-up and data entry from the workflow, eliminating nearly 50
percent of the hands-on time compared with traditional systems,
significantly reducing cost of ownership as well as cost per test.
Additionally, the Project 24 provides Magellan with a
powerful platform for future development, including multiplexed
immunoassay and molecular testing.”
According to Magellan Chief Innovation Officer, Adrian Bunce,
“The heart of Project 24 lies in its revolutionary
approach to assay kit packaging. Rather than the manual reagent
loading and data input of current systems, we have vastly
simplified the process – working with assay manufacturers to
develop pre-loaded kits that the user adds directly from the box.
The direct-load kit format eliminates the need for manual reagent
transfer and includes a barcode system that electronically
communicates all the information needed for a successful run.